• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.

作者信息

Ozaki Shuji, Harada Takeshi, Fujii Shiro, Nakamura Shingen, Miki Hirokazu, Nakano Ayako, Kagawa Kumiko, Takeuchi Kyoko, Abe Masahiro, Matsumoto Toshio

机构信息

Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.

Department of Hematology, Tokushima University Hospital, Tokushima, Japan.

出版信息

Int J Hematol. 2011 Feb;93(2):257-259. doi: 10.1007/s12185-011-0775-1. Epub 2011 Feb 1.

DOI:10.1007/s12185-011-0775-1
PMID:21279817
Abstract
摘要

相似文献

1
Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.来那度胺联合小剂量地塞米松治疗两名复发多发性骨髓瘤患者期间的短暂炎症反应
Int J Hematol. 2011 Feb;93(2):257-259. doi: 10.1007/s12185-011-0775-1. Epub 2011 Feb 1.
2
Treatment of relapsed and refractory myeloma.复发性和难治性骨髓瘤的治疗。
Curr Hematol Malig Rep. 2009 Apr;4(2):99-107. doi: 10.1007/s11899-009-0014-5.
3
Lenalidomide and its role in the management of multiple myeloma.来那度胺及其在多发性骨髓瘤治疗中的作用。
Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74. doi: 10.1586/14737140.8.6.865.
4
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.来那度胺联合地塞米松治疗复发或难治性多发性骨髓瘤患者，无论之前是否使用过沙利度胺，均比单独使用地塞米松更有效。
Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.
5
Spotlight on lenalidomide in relapsed or refractory multiple myeloma.聚焦来那度胺治疗复发/难治性多发性骨髓瘤。
BioDrugs. 2011 Oct 1;25(5):333-7. doi: 10.2165/11207120-000000000-00000.
6
Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.来那度胺：治疗复发性或难治性多发性骨髓瘤的研究进展。
Drugs. 2011 Mar 26;71(5):625-49. doi: 10.2165/11206420-000000000-00000.
7
Lenalidomide in the treatment of multiple myeloma: a review.来那度胺治疗多发性骨髓瘤的综述
J Clin Pharm Ther. 2008 Jun;33(3):219-26. doi: 10.1111/j.1365-2710.2008.00920.x.
8
Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma.
Nat Rev Clin Oncol. 2009 May;6(5):247-8. doi: 10.1038/nrclinonc.2009.50.
9
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.来那度胺联合地塞米松治疗复发或难治性多发性骨髓瘤。
N Engl J Med. 2007 Nov 22;357(21):2123-32. doi: 10.1056/NEJMoa070594.
10
Lenalidomide: an update on evidence from clinical trials.来那度胺：临床试验证据的更新。
Blood Rev. 2010 Nov;24 Suppl 1:S21-6. doi: 10.1016/S0268-960X(10)70005-9.

引用本文的文献

1
Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.来那度胺在体内和体外均可增强骨髓瘤特异性T细胞反应。
Oncoimmunology. 2016 Feb 18;5(5):e1139662. doi: 10.1080/2162402X.2016.1139662. eCollection 2016 May.
2
Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.来那度胺联合地塞米松治疗多发性骨髓瘤过程中 Th1 和 Th2 细胞因子与短暂性炎症反应的相关性。
Int J Hematol. 2013 Jun;97(6):743-8. doi: 10.1007/s12185-013-1321-0. Epub 2013 Apr 23.
3
Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.

本文引用的文献

1
Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma.来那度胺联合地塞米松治疗复发/难治性多发性骨髓瘤的日本患者。
Int J Hematol. 2010 Jul;92(1):118-26. doi: 10.1007/s12185-010-0624-7. Epub 2010 Jun 18.
2
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.免疫调节药物（IMiDS）在多发性骨髓瘤中的作用机制。
Leukemia. 2010 Jan;24(1):22-32. doi: 10.1038/leu.2009.236. Epub 2009 Nov 12.
3
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
接受来那度胺发热反应的复发多发性骨髓瘤患者的细胞因子谱
Int J Hematol. 2011 Dec;94(6):583-4. doi: 10.1007/s12185-011-0973-x. Epub 2011 Nov 30.
来那度胺联合高剂量地塞米松与来那度胺联合低剂量地塞米松作为初治多发性骨髓瘤的初始治疗：一项开放标签随机对照试验。
Lancet Oncol. 2010 Jan;11(1):29-37. doi: 10.1016/S1470-2045(09)70284-0. Epub 2009 Oct 21.
4
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.来那度胺诱导肿瘤细胞上CD80上调与T细胞活化、细胞因子释放综合征的快速发作以及慢性淋巴细胞白血病中白血病细胞清除相关。
Haematologica. 2009 Sep;94(9):1266-73. doi: 10.3324/haematol.2009.005835.
5
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.来那度胺可使复发难治性慢性淋巴细胞白血病患者获得完全缓解和部分缓解。
Blood. 2008 Jun 1;111(11):5291-7. doi: 10.1182/blood-2007-12-130120. Epub 2008 Mar 11.
6
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.来那度胺联合地塞米松治疗北美复发多发性骨髓瘤
N Engl J Med. 2007 Nov 22;357(21):2133-42. doi: 10.1056/NEJMoa070596.
7
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.来那度胺联合地塞米松治疗复发或难治性多发性骨髓瘤。
N Engl J Med. 2007 Nov 22;357(21):2123-32. doi: 10.1056/NEJMoa070594.
8
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis.人C反应蛋白结合活化的Fcγ受体并保护骨髓瘤肿瘤细胞免于凋亡。
Cancer Cell. 2007 Sep;12(3):252-65. doi: 10.1016/j.ccr.2007.08.008.
9
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.单克隆丙种球蛋白病、多发性骨髓瘤及相关疾病的分类标准：国际骨髓瘤工作组报告
Br J Haematol. 2003 Jun;121(5):749-57.